Page 5 - Immunotherapy Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Credit: UPMC PITTSBURGH, Feb. 4, 2021 - Researchers at UPMC Hillman Cancer Center and the National Cancer Institute (NCI) demonstrate that changing the gut microbiome can transform patients with advanced melanoma who never responded to immunotherapy--which has a failure rate of 40% for this type of cancer--into patients who do. The results of this proof-of-principle phase II clinical trial were published online today in Science. In this study, a team of researchers from UPMC Hillman administered fecal microbiota transplants (FMT) and anti-PD-1 immunotherapy to melanoma patients who had failed...

physician-scientist Leisha A. Emens, M.D., Ph.D., has been presented with the Sy Holzer Endowed Immunotherapy Research Fund Award to advance innovative research in cancer. Internationally recognized for her work in breast cancer immunotherapy, Emens is co-leader of the Cancer Immunology and Immunotherapy Program and director of Translational Immunotherapy for the Women’s Cancer Research Center at UPMC Hillman. Emens has developed innovative combination immunotherapies that incorporate cancer vaccines, immune checkpoint inhibitors and other immune modulators with standard and novel treatme...

 E-Mail IMAGE: UNC Lineberger Comprehensive Cancer Center's Jonathan S. Serody, MD, and colleagues report that adding a small molecule to a chimeric antigen receptor-T (CAR-T) cell therapy can help immune system T... view more  Credit: UNC Lineberger Comprehensive Cancer Center CHAPEL HILL, NC--Boosting immune system T cells to effectively attack solid tumors, such as breast cancers, can be done by adding a small molecule to a treatment procedure called chimeric antigen receptor-T (CAR-T) cell therapy, according to a study by researchers at the UNC Lineberger Comprehensive Cancer Ce...